Key Highlights

  • VYNE Therapeutics (NASDAQ: VYNE) declared a special cash dividend of $0.38 per share, totaling approximately $16.5 million.
  • The dividend is contingent on the completion of VYNE’s merger with Yarrow Bioscience, expected to close around July 24, 2026.
  • Payment will be made to shareholders of record as of July 22, 2026, with distribution following the dividend payment date of July 23.
  • The merger requires approval from VYNE’s stockholders at a special meeting scheduled for July 16, 2026.

Dividend Announcement Details

VYNE Therapeutics Inc. (NASDAQ: VYNE) has declared a special cash dividend of $0.38 per share, amounting to an estimated $16.5 million in total. The dividend is tied to the company’s pending merger with Yarrow Bioscience, a transaction first announced in December 2025. The payout reflects VYNE’s net cash position exceeding $0 prior to the merger’s closing.

Record and Payment Dates

The dividend will be distributed to shareholders of record as of July 22, 2026. VYNE’s transfer agent will receive the funds on July 23, with actual payments to investors expected within days.

Merger Dependency

The special dividend is conditional on the completion of VYNE’s merger with Yarrow Bioscience. The transaction, structured as a reverse merger, will see Yarrow become a wholly owned subsidiary of VYNE. Closing is targeted for July 24, 2026, pending stockholder approval and other customary conditions.

Stockholder Vote Scheduled

VYNE’s board has called a special stockholder meeting for July 16, 2026, to vote on the merger agreement. Approval is required for the transaction to proceed, which would finalize the combination of the two biotech firms. The outcome of the vote will directly impact the dividend’s payment.

Forward-Looking Considerations

The company has cautioned that the dividend amount and merger timeline remain subject to change. Risks include potential failure to secure stockholder approval, regulatory hurdles, or unforeseen developments that could delay or derail the transaction. VYNE’s projections are based on current expectations and assumptions.

Financial and Operational Risks

The merger’s completion could affect VYNE’s financial position, including its cash reserves and operating expenses. The combined entity will face challenges such as managing unanticipated costs, advancing product candidates, and managing regulatory pathways. Intellectual property and clinical trial outcomes also pose key risks.

Next Steps for Investors

Shareholders should monitor the July 16 vote and subsequent merger updates. The dividend’s final amount may vary based on VYNE’s net cash position at closing. Investors are advised to review the company’s SEC filings for detailed risk disclosures related to the transaction.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.